Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

Bendix, Mia; Dige, Anders; Jørgensen, Søren Peter; Dahlerup, Jens Frederik; Bibby, Bo Martin; Deleuran, Bent; Agnholt, Jørgen

doi:10.3390/nu12123699

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

Mia Bendix

^1,*,

Anders Dige

¹,

Søren Peter Jørgensen

¹,

Jens Frederik Dahlerup

Bo Martin Bibby

²,

Bent Deleuran

^3,4 and

Jørgen Agnholt

Department of Hepatology and Gastroenterology, Aarhus University Hospital, 8200 Aarhus, Denmark

Department of Public Health—Department of Biostatistics, Aarhus University, 8000 Aarhus, Denmark

Department of Rheumatology, Aarhus University Hospital, 8200 Aarhus, Denmark

⁴

Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark

Author to whom correspondence should be addressed.

Nutrients 2020, 12(12), 3699; https://doi.org/10.3390/nu12123699

Received: 5 November 2020 / Revised: 24 November 2020 / Accepted: 26 November 2020 / Published: 30 November 2020

(This article belongs to the Special Issue Nutritional Management for Inflammatory Bowel Diseases)

View Full-Text Download PDF

Browse Figures

Review Reports Citation Export

Abstract

Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34. View Full-Text

Keywords: vitamin D treatment; Crohn’s disease; infliximab

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 28 KiB)

Share and Cite

MDPI and ACS Style

Bendix, M.; Dige, A.; Jørgensen, S.P.; Dahlerup, J.F.; Bibby, B.M.; Deleuran, B.; Agnholt, J. Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab. Nutrients 2020, 12, 3699. https://doi.org/10.3390/nu12123699

AMA Style

Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab. Nutrients. 2020; 12(12):3699. https://doi.org/10.3390/nu12123699

Chicago/Turabian Style

Bendix, Mia, Anders Dige, Søren P. Jørgensen, Jens F. Dahlerup, Bo M. Bibby, Bent Deleuran, and Jørgen Agnholt. 2020. "Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab" Nutrients 12, no. 12: 3699. https://doi.org/10.3390/nu12123699

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI